Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185) has released an update.
Shanghai Bio-Heart Biological Technology Co., Ltd. has announced its participation as a limited partner in a new limited partnership in China, along with Guojian Jinquan as the general partner and Mr. Jing Bao as a limited partner. The partnership, which will focus on technology and medical research, involves a total capital contribution of RMB54.30 million, with the company contributing approximately 60.4%. The transaction is classified as discloseable under Hong Kong’s listing rules.
For further insights into HK:2185 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com